Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC012F in BCMA+ Refractory/Relapsed Multiple Myeloma
NCT04236011Phase 1Unknown
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Jan 2020
- Primary completion
- Jul 2022
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GC012 in multiple myeloma (MM), sponsored by Shanghai Changzheng Hospital. Primary endpoint: Incidence and severity of adverse events after GC012F infusion at 24 weeks. Status: unknown.
02
Drugs
GC012
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04236011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04236011.